#MSParis2017 – TG Therapeutics’ Ublituximab Depletes Harmful B-cells and Lowers MRI Lesions, Trial Shows
News
TG Therapeutics’ ublituximab nearly eradicated a type of immune B-cell believed to be involved in multiple sclerosis, according to a Phase 2 clinical trial.
The result was that none ... Read more